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PENGKLONAN DAN PENGEKSPRESAN PROTEIN GA DALAM SISTEM YIS 
Abstrak 
Sedekad yang lepas, serangan jangkitan Nipah virus (NiV) di seluruh dunia telah 
menunjukkan kadar kematian setinggi 92%. NiV merupakan wabak yang amat bahaya 
kepada manusia and juga binatang. Oleh itu, pembangunan vaksin telah menjadi satu 
strategi yang penting untuk mencegah wabak ini. Menurut kajian sebelum ini, glikoprotein 
NiV (NiV-G) telah diklonkan dalam vektor pengekspresan yis Pichia pastoris (pZMF) 
yang dikawal oleh promoter AOXI. Walau bagaimanapun, pengekspresan rekombinan 
glikoprotein G dalam sistem ini didapati tidak stabil. Oleh itu, kestabilan rekombinan 
protein dikaji dengan mengklonkan sebahagian gen (gen GA) yang disyaki sebagai 
penyebab ketidakstabilan dalam sistem biologikal yang sama. Penghasilan rekombinan 
protein dalam yis dikesan melalui analisis Western blot. Kajian ini telah menunjukkan 
bahawa pengekspresan protein rekombinan adalah stabil and konsisten dengan berat 
molekul sebanyak 40 kDa. Berat molekul protein rekombinan sebanyak 40 kDa ini telah 
mencadangkan bahawa rekombinan gen GA adalah stabil dalam pengekspresan 
keseluruhan gene NiV -G. Tambahan pula, rekombinan protein yang dihasilkan boleh 
dijadikan sebagai vaksin sekiranya protein ini didapati potensi antigenik dan immuogenik 
yang tinggi. 
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CLONING AND EXPRESSION OF GA PROTEIN OF NIPAH VIRUS IN YEAST 
EXPRESSION SYSTEM 
Abstract 
Nipah virus (NiV) is a deadly zoonotic paramyxovirus that has emerged and re-
emerged over the last 10 years. In human, the infection leads to encephalitis with 92% 
mortality rate. This has underlined the importance for the development of a vaccine 
candidate in preventing such zoonotic disease. In previous study, the gene encoding the 
NiV glycoprotein (NiV -G) was cloned into the yeast Pichia Pastoris expression vector 
(pZMF) under the control of AOXI promoter. However, the recombinant G glycoprotein 
expression was found to be highly unstable in this system. Therefore, the stability of the 
recombinant protein was investigated by studying one of the truncated gene fragment (GA 
gene). The truncated gene encoding the gene sequence 1-867 was cloned and expressed in 
the same biological system. The detection of the truncated recombinant protein was 
performed through Western blot analysis. The result of this study indicated that the 
truncated fragment was stable and the expression was consistent with protein molecular 
weight of 40 kDa. The absent of degradation incident in this study had suggested that GA 
gene fragment was stable in full length G-glycoprotein expression. In addition, the 
truncated recombinant protein could be utilized as a promising vaccine candidate if the 
recombinant protein was found to be highly antigenic and immunogenic. 
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Chapter 1: Introduction 
Nipah virus (NiV) is a deadly emerged virus found to be the etiology agent in an 
outbreak of severe febrile encephalitis in human. It had been classified under the family of 
Paramyxoviridae under a new genus of Henipavirus ( 1999). Its genome encodes six 
structural proteins: nucleocapsid (N), phosphor- (P), matrix- (M), fusion- (F), glyco- (G), 
and large- (L) protein (Harcourt et a/., 2000, Wong et a/., 2001) 
The first outbreak of NiV occurred in 1998 and 1999 in Penisular Malaysia. It 
affected 265 patients nationwide with more than I 05 mortalities. NiV has continue to 
reemerged, with outbreaks in Bangladesh in 2001 and 2003 (Hsu et a/., 2004). Further 
outbreak had occurred in Bangladesh in early 2004 and 2005. The most recent outbreak 
occurred in India and Bangladesh in 2007, and it was associated with a higher incidence of 
acute respiratory distress syndrome which happened concurrently with encephalitis, person-
to-person transmission and with a fatality rate of75% (Gurley eta/., 2007). 
NiV had been classified as a zoonotic bio-safety level 4 (BSL-4) agent and was 
included as one of the pathogenic agent of bio-defense concern by the Centers for Disease 
Control and Prevention (CDC}, and National Institute of Allergy and Infectious Diseases 
(NIAID). Therefore, the strategy of prevention (vaccination) for such a zoonotic disease has 
become a priority. The use of vaccine is the most efficient and cost-effective method in 
preventing infectious diseases. 
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In previous study, NiV glycoprotein (NiV-G) gene fragment was cloned into the 
Pichia expression vector (yeast system) for the production of a recombinant protein. 
However, the molecular weight of the recombinant protein expressed was found to be 
smaller than expected. Similarly, a smaller protein fragment was obtained in the bacteria 
expression system with an identical gene. These results had suggested that the translated 
recombinant NiV -G protein was highly unstable and susceptible to be degraded by the host 
machinery. 
Therefore, the instability of the recombinant protein was investigated by studying 
one of the truncated gene fragments. The truncated gene encoding the gene sequence 1-870 
was cloned and expressed in the same biological system. The detection of the truncated 
recombinant protein was performed through Western blot analysis. Besides identifYing the 
root of degradation, the truncated recombinant protein could be utilized as a promising 
vaccine candidate if it was found to be highly antigenic and immunogenic. 
NiV -G was chosen for vaccine development based on the study done by Guillaume 
et a/. (2004a) and Tamin et a/. (2002). These studies had proven that NiV -G protein was 
highly antigenic and immunogenic. The administration of subunit vaccine which expressed 
the NiV -G and NiV -F (Fusion protein) protein protected the animal model from lethal NiV 
infection. Additionally, NiV-G is the most important target for the production of 
neutralizing antibodies (Tamin et al., 2002) 
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In this study, NiV -G was expressed in yeast Pichia past oris expression system. 
Yeast, as an eukaryote it offered the major advantage of posttranslational modification (Liu 
et al., 2004). Many proteins that end up as an inactive inclusion bodies in bacterial system 
are produced as biologically active molecules in P. pastoris (Juozapaitis et al., 2006). 
Besides, yeast expression system is generally regarded as faster, easier, and less expensive 
compared to the expression systems derived form higher eukaryotes, such as insect and 
mammalian tissue culture cell systems. 
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Chapter 2: Review of Literature 
2.1 Outbreak of Nipab virus 
An outbreak of encephalitis primarily affecting pig farmers had occurred during 
1998-1999 in Malaysia (Chua et al., 1999). 265 cases of severe febrile encephalitis were 
reported in Perak, Negeri Sembilan, and Selangor with 40% of fatality rate. By the end of 
May 1999, it was spread to the neighboring country, Singapore. II cases with 1 death had 
been reported among abattoir workers who slaughtered pigs which were imported from 
affected areas of Malaysia (Paton et al., 1999). 
In 2001, an outbreak of acute encephalitis had emerged in Siliguri (West Bengal) 
town of India between January 31 and February 23. A total of 66 probable cases with 45 
deaths were reported (Harit et al., 2006). 
In Bangladesh, a few outbreak of acute encephalitis had emerged with 9 deaths were 
reported in Mehepur district in 2001 (Hsu et al., 2004), 8 deaths were reported in Naogoan 
district in 2003 (Hsu et al., 2004), I death was reported in Rajbari districts in 2004 (Quddus 
et al., 2004), 27 deaths with 75% fatality rate were reported in Faridpur district in 2004 
(Gurley et al., 2001), 11 deaths with 92% fatality rate were reported in Tangail district in 
2005 (ICDDR, 2005), and 8 deaths were reported in Rajbari and Manikgonj in 2008 
(ICDDR, 2008). 
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2.2 Transmission of the disease 
Originally, NiV was transmitted from fruit bats to domestic animals (pigs). The 
most likely initiating event was the shedding of the NiV in their saliva on the partial eaten 
fruit (Yob et al., 2001). Pigs were infected when they contacted with the infective saliva. 
This was supported by the evidence during the Malaysian outbreak occurred in 1999. The 
affected farm was found to be located in close proximity with the tropical forest, habitat of 
the fruit bats (Chua eta/., 1999). 
In the Malaysian outbreak, NiV was found to be transmitted from infected pig to 
human. Most of the infected individual was occupationally associated with pigs either as 
the pig farmers or abattoir workers (Paton eta/., 1999; Sahani eta/., 2001; Chan eta/., 
2002) . According to Chong et a/. (2003), the direct transmission of NiV from bats to 
human was low. This was due to the inadvertent direct contact with bats or bats' secretion. 
During the Malaysian outbreak, a person-to-person transmission of NiV was not 
documented (Mounts eta/., 2001 ). 
Conversely, a person-to-person transmission was demonstrated during the outbreak 
of NiV in Faridpur District, Bangladesh in year 2004. Detection of NiV RNA on hospital 
surfaces indicated that the infected patients shed virus into the environment which provided 
an opportunity to transmit NiV to the others. The health workers and hospital visitors were 
infected after exposure to hospitalized patients with NiV illness (Gurley eta/., 2007). In 
contrast, the absent of person-to-person transmission in Malaysia and Singapore could be 
due to differences in patient care practices (Gurley eta/., 2007). 
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During the subsequent outbreak in Tangail District, Bangladesh in 2005, a direct 
transmission ofNiV from bat to human was reported. Bats were attracted by the agriculture 
of foods that available seasonally and this had brought the bats into proximity with humans. 
The infective saliva and urine from the bats had contaminated the date palm sap and human 
was infected by drinking the fresh, raw date palm sap (Luby et al., 2006). 
2.3 Isolation of aetiological agent 
A novel paramyxovirus, named as Nipah Virus was firstly isolated from 
cerebrospinal fluid of a patient from the village of Sungai Nipah in March 1999 (Chua et al., 
1999, Chua et al., 2000). Subsequently, NiV was isolated from Malaysian Island flying-
foxes and the serological evidence had suggested that it was one of the natural hosts for the 
NiV (Chua et al., 2002). In 2004, NiV from experimental infected pigs was isolated and 
sequenced. The findings showed two possible origins of NiV that contributed to the 
Malaysia outbreaks from 1998 to 1999 (AbuBakar et al., 2004). 
Continuously, NiV had been isolated in Cambodia (Reynes et al., 2005), 
Bangladesh (Harcourt et al., 2005), ThaiJand (Wacharapluesadee et al., 2005), and India 
(Chadha et al., 2006). The NiV isolated from four human cases in Bangladesh had shown a 
significant NiV genetic heterogeneity. These datas suggested that there were multiple 
introductions ofNiV into the population. These datas also suggested that viruses circulating 
in different areas have unique genetic signatures and these strains may have co-evolved 
within local natural reservoir. 
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2.4 Molecular characterization of Nipah virus 
NiV had been characterized under the subfamily of Paramyxovirinae within the 
family Paramyxoviridae and genus of Henipavirus. The phylogenetic analysis for NiV 
illustrated that it does not group under any of the established genera of the subfamily 
Paramyxovirinae. Furthermore, the unique features of the NiV genome, the broad host 
range and antigenic cross-reactivity clearly indicates that NiV should be considered as a 
new genus within the subfamily ofParamyxovirinae (Harcourt et al., 2000). 
2.5 The origin of Nipah virus 
Pterious bats served as the natural reservoir of NiV. This was proven by a 
serological diagnostic survey in bats with the demonstration of neutralizing antibodies 
against NiV-infection (Yob et al., 2001). The virus was later isolated from urine and partial 
eaten fruit of flying floxes (Pterious hypomelanus)(Chua et al., 2002). As a consequence of 
recent ecological changes such as deforestation, the natural habitat of the fruit bats had 
been destructed. This caused the migration of bats to live closer to human and domestic 
animals which facilitated the transmission of virus to new species. As a result, the zoonoses 
had become more pathogenic (Guillaume et al., 2004a). 
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2.6 Strategy of prevention and treatment of Nipah virus infection 
The outbreak ofNiV poses a major health problem worldwide, which would destroy 
the economies of many countries. Therefore, there is a demand for rapid detection as well 
as serological diagnostic for the monitoring of the disease. Besides, the development of 
vaccine candidate is rather important to protect the high risk population such as BSL-4 staff 
and the first responder who may encounter the virus. 
2.6.1 Development of animal model 
The developments of animal models are important especially for newly-emerged 
viruses, to understand the pathology and pathogenesis of the disease. Primarily, Wong et al. 
(2003) had demonstrated that golden hamster was a suitable model for NiV infection. It 
produced a similar pathogenesis as in NiV -infected human. Further study indicated that 
hamster model was able to develop a neutralizing antibody following the recombinant NiV 
subunit immunization. However, both relapsing and late-onset cases of infection had not 
been observed in this model (Guillaume et al., 2004a; Guillaume et al., 2006). 
Subsequently, experimental NiV infections in cats were performed. The findings had 
indicated that cats provide a consistent model for acute NiV infection and associated 
pathogenesis (Mungall et al., 2006). Recently, the preliminary study of Bossart et al. (2007) 
had suggested that ferret might be a potential study model for NiV infection. 
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2.6.2 Development of rapid diagnostic test 
The high mortality rate which established in NiV infection had underlined the 
importance of rapid diagnostic test in wild, domestic animal, and human. However ., the 
diagnostic tests were restricted by the limitation of BSL-4 facilities in most oi' the 
developing countries. Therefore, most of the researchers had developed a diagnostic sy stem 
without BSL-4 faci lities such as the rapid immune plaque assay, real-time RT-PCR a ssay 
and Enzyme-Linked ImmunoSorbent Assay (ELISA). 
Initially, a rapid immune plaque assay had been developed by Crameri eta/. (2001) 
for rapid detection and quantification of the NiV and anti-viral antibody. It involved NiV 
infection on monolayer Vera cell line from the biological samples (if present). The an_t igen 
in the infected cell was detected by antibodies generated by a bacteria-expressed portion of 
HeY P protein. However, the test was time consuming. It required more than 24 hour s for 
the detection of syncytia formation in order to perform antibody testing. Besides, the test 
was not specific to detect the NiV since both NiV and HeV infection could no t be 
differentiated. However, this assay was able to be performed in laboratories that do not 
have the BSL-4 facilities (Crameri eta/., 2001). 
Continuously, a TaqMan™ real time RT-PCR of NiV nucleoprotein had been 
developed by Guillaume et a/. (2004b ). It has advantage over plaque assays whe re it 
provides rapid (few hours), quantitative and specific results. Importantly, TaqMan™- RT-
PCR can be utilized as a differential diagnostic test between NiV and HeV infection as it is 
unable to detect Hendra virus DNA. Besides, the assay had been prove n validl for 
monitoring the NiV in serum samples from infected animals (Guillaume et al., 2004b). 
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A duplex nested RT-PCR (nRT-PCR) ofNiV nucleoprotein had been developed by 
Wacharapluesadee eta/. (2007). The sensitivity of the nRT-PCR was found to be higher 
than Nipah TaqMan™ assay as reported previously (Guillaume eta/., 2004b). The findings 
from the study had found that nRT-PCR assay was suitable for NiV surveillance in the wild, 
domestic animals and for diagnostic of human disease. 
In 2004, a solid-phase blocking ELISA utilizing monoclonal antibody (MAb) 
specific to NiV had been developed for detection of antibodies to NiV. It shows no cross-
reaction with HeV. Therefore the test was specific. Furthermore, it involved quick and 
simple procedure compared to the existing indirect ELISA (Kashiwazaki eta/., 2004). 
In advance, a recombinant protein for NiV-nucleoprotein (Eshaghi et al., 2005; 
Juozapaitis et al., 2006; Yu et al., 2006), NiV-glycoprotein (Wang eta/., 2006b), and NiV-
fusion protein (Wang et al., 2006b) had been expressed in different systems for the 
development of a recombinant protein-based ELISA diagnostic test. The recombinant 
protein-based ELISA was found to be more sensitive to the inactivated-virus-based ELISA 
(Yu et al., 2006). In addition, it is a safer method for diagnostic since it does not involve 
inactivation of a live virus. It eliminates the requirement of a BSL-4 laboratory during the 
diagnostic preparation. Furthermore, the production of recombinant protein is rapid and 
cost-effective. Therefore, this method is especially useful in cases of large-scale 
epidemiological investigations, as well as in developing countries where high-security 
laboratory are not available. 
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2.6.3 Development of vaccine (animal) 
The development of vaccine is useful in preventing the transmission of disease in 
future NiV outbreak. Additionally, vaccination on the high risk groups is rather important 
to protect them from the lethal infection. Up to date, a vaccine candidate had been 
successfully developed in swine. Besides, some animal trial had been performed in hamster, 
mice and cat model. 
A recombinant vaccinia virus-based vaccine encoding NiV-F (VV-NiV.F) and NiV-
G (VV-NiV.G) glycoprotein was firstly developed in golden hamster model (Gui11aume et 
al., 2004a). In this study, co-infection of VV-NiV.F and VV-NiV.G was found to protect 
the animal model against NiV challenge. It obtained high antibody levels but relatively low 
neutralizing antibodies. In contrast, a higher titer of neutralizing antibodies was found in 
the mice which had been vaccinated with a different strain of vaccinia virus, wild-type (WT) 
vaccinia (WR strain) (Tamin et al., 2002). However, WR virus was much more virulent and 
grew to high titers in several organs. 
Vaccination with a combination of recombinant canarypox virus-based vaccine 
encoding NiV-G glycoprotein and F fusion protein (ALVAC-F/G) had successfully 
protected pigs from NiV challenge (Weingartl et al., 2006). The sera from the AL VAC-
F /G-vaccinated animals showed a moderate neutralizing activity against the related He V. 
These findings had gained more information regarding the immunogenicity of the vaccine. 
It proved the possibility to protect the NiV infection with a single vaccine. 
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A subunit vaccine formulation containing recombinant, soluble, and attachment 
glycoprotein from HeV (sGHev) and CpG adjuvant was found to be able to protect the cat 
models from NiV lethal infection (McEachern et al., 2008). A CpG adjuvant had been 
employed to stimulate mucosal and Thl immunity. The combination of sGHeV and CpG 
had induced a sufficient level of antigen-specific plasma lg, neutralizing antibodies and 
anti-specific mucosal IgA. 
Recently, a NiV G and F gene had been constructed in the mammalian expression 
vector pCAGGS under chicken beta-actin promoter. The boosting of pCAGG-NiV-F and 
pCAGG-NiV-G expression vector into six-week-old female mice (BALB/c) had stimulated 
the production of a specific antibody. Furthermore, this antibody was able to neutralize the 
infection of VSVdeltaG*F/G (NiV G and F envelope glycoproteins pseudotyped 
recombinant vesicular stomatitis virus expressing green fluorescence protein). Thus, DNA 
vaccination ofNiV-F/G could be an efficient vaccine strategy against NiV infection (Wang 
et al., 2008). 
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Chapter 3: Objective 
The main aims of works that had been carried out were:-
1. To amplify a truncated NiV-G gene named as GA gene. 
2. To propagate the recombinant plasmid using conventional transformation method in 
bacterial system. 
3. To express the GA gene in yeast expression system. 
4. To demonstrate the presence of recombinant protein by mean of SDS-PAGE and 
Western Blot 
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Chapter 4: Experimental Overview 
The flow chart of experimental overview in this study was shown as below. 
PCR amplification of GA gene 
Construction of recombinant plasmid (pZMF-GA) 
Transformation of pZMF-GA into bacteria system 
Verification ofpZMF-GA by PCR and restriction enzyme digestion 
Transformation of pZMF-GA into yeast expression system 
Methanol induction for recombinant protein expression 
Western blot analysis 
